Lineage Cell Therapeutics, Inc. 8-K Filing
Ticker: LCTX · Form: 8-K · Filed: Nov 28, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lineage Cell Therapeutics, Inc. (ticker: LCTX) to the SEC on Nov 28, 2025.
How long is this filing?
Lineage Cell Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 576 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 14.8 · Accepted 2025-11-28 16:05:24
Filing Documents
- lctx-20251128.htm (8-K) — 41KB
- 0001193125-25-302552.txt ( ) — 141KB
- lctx-20251128.xsd (EX-101.SCH) — 23KB
- lctx-20251128_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously reported, Lineage Cell Therapeutics, Inc. (the "Company") applied for a Clinical Trial (CLIN2) award (the "CIRM Grant") from the California Institute for Regenerative Medicine ("CIRM") in June 2025 to support continued clinical development of OPC1 for the treatment of spinal cord injuries ("SCI"). On November 28, 2025, the Company elected to withdraw its application for the CIRM Grant following comments to the application received by the Company from CIRM on November 24, 2025. There were no specific content deficiencies identified by CIRM in the Company's grant application, and based on discussions between the Company and CIRM representatives held on November 25, 2025, the Company intends to respond to the feedback it received from CIRM on its application and submit a revised application in the next available CIRM grant application cycle, currently scheduled for January 2026. Neither the withdrawal of the Company's current application nor the planned resubmission of a revised application impact the Company's current and planned development of OPC1 or the ongoing DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study to evaluate the safety and utility of a novel spinal cord delivery device designed to administer OPC1 to the spinal parenchyma in both subacute (between 21 to 42 days following injury) and chronic (between 1 to 5 years following injury) SCI participants.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lineage Cell Therapeutics, Inc. Date: November 28, 2025 By: /s/ George A. Samuel III Name: Title: George A. Samuel III General Counsel and Corporate Secretary